Non-muscle invasive bladder cancer (NMIBC) has one of the highest local recurrence rates of any malignancy. The current standards of care for NMIBC surveillance are white light cystoscopy and urine cytology. However, novel surveillance tests are needed to improve the detection of recurrent NMIBC. A recent study by Cochetti et al. examined the performance of Bladder EpiCheck (BE), a urine test that assesses 15 methylation biomarkers and photodynamic diagnosis (PDD)-guided cystoscopy for surveillance of high-risk NMIBC.